KBI Biopharma, a biopharmaceutical contract development and manufacturing organization, has signed an agreement with Pelican Therapeutics, a subsidiary of Heat Biologics, a Durham, North Carolina-headquartered clinical-stage biotechnology company, for cGMP production of its PTX-35 antibody and PTX-15 fusion protein for treating cancer.

Under the agreement, KBI Biopharma will offer development and manufacturing services.  In May 2016, Pelican was awarded a $15.2-million grant from the Cancer Prevention and Research Institute of Texas to support these manufacturing efforts as well as to complete a 70-patient, Phase I clinical trial incorporating one or more of these compounds.

Source: Heat Biologics